Trade Report: Today, 1,030 Shares of Momenta Pharmaceuticals Inc. (MNTA) Stock are sold by Bruce Leicher

Today, 1,030 Shares of Momenta Pharmaceuticals Inc. (MNTA) Stock are sold by Bruce Leicher

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 1,030 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $13.66, for a total value of $14,069.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 13.90 on Friday. The stock has a 50 day moving average price of $12.27 and a 200 day moving average price of $11.65. Momenta Pharmaceuticals Inc. has a 1-year low of $7.86 and a 1-year high of $18.26. The company’s market cap is $958.50 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. The business had revenue of $299.14 million for the quarter, compared to the consensus estimate of $25.68 million. During the same period last year, the business posted ($0.44) EPS. The business’s revenue was up 2067.7% compared to the same quarter last year. On average, equities research analysts anticipate that Momenta Pharmaceuticals Inc. will post ($1.16) EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Fiera Capital Corp bought a new position in shares of Momenta Pharmaceuticals during the second quarter worth about $26,019,000. Sector Gamma AS increased its position in shares of Momenta Pharmaceuticals by 83.8% in the first quarter. Sector Gamma AS now owns 780,313 shares of the biotechnology company’s stock valued at $7,210,000 after buying an additional 355,777 shares during the period. BlackRock Fund Advisors increased its position in shares of Momenta Pharmaceuticals by 6.8% in the third quarter. BlackRock Fund Advisors now owns 5,258,020 shares of the biotechnology company’s stock valued at $61,466,000 after buying an additional 335,064 shares during the period. FMR LLC increased its position in shares of Momenta Pharmaceuticals by 2.6% in the second quarter. FMR LLC now owns 10,632,879 shares of the biotechnology company’s stock valued at $114,835,000 after buying an additional 265,713 shares during the period. Finally, Palo Alto Investors LLC increased its position in shares of Momenta Pharmaceuticals by 10.9% in the second quarter. Palo Alto Investors LLC now owns 1,629,076 shares of the biotechnology company’s stock valued at $17,594,000 after buying an additional 160,300 shares during the period. Institutional investors and hedge funds own 81.62% of the company’s stock.

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. Barclays PLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Cowen and Company reaffirmed a “hold” rating on shares of Momenta Pharmaceuticals in a report on Sunday, August 7th. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 10th. Finally, Maxim Group reaffirmed a “sell” rating and set a $6.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $16.10.

Momenta Pharmaceuticals Company Profile

Related posts

Leave a Comment